Clinical Trial Update: Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch) [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of serlopitant for pruritus was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Prurigo Nodularis
• Pruritus
• Psoriasis

Drugs mentioned

• Serlopitant (serlopitant)

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Pruritus, Prurigo Nodularis | Phase 3 | Status: TERMINATED | Results posted: 2020-11-30